<PAGE>
--------------------------------------------------------------------------------


                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                                   FORM 10-QSB

   [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
                                   ACT OF 1934


                  FOR THE QUARTERLY PERIOD ENDED JUNE 28, 2003

                                       OR

      [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT


                          COMMISSION FILE NUMBER 0-9478
                           __________________________

                           SPECTRUM LABORATORIES, INC.
             (Exact name of Registrant as specified in its charter)

             DELAWARE                                   95-4718363
   (State or other jurisdiction             (I.R.S. Employer Identification No.)
of incorporation or organization)


           18617 BROADWICK STREET, RANCHO DOMINGUEZ, CALIFORNIA 90220
         (Address of principal executive offices)             (zip code)

       Registrant's telephone number, including area code: (310) 885-4600

Indicate by check mark whether the issuer (1) filed all reports required to be
filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or
for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
Yes [X] No [ ]

   Number of shares of Common Stock outstanding as of July 31, 2003: 5,312,468

                  TRANSITIONAL SMALL BUSINESS DISCLOSURE FORMAT

                                 YES [ ] NO [X]

--------------------------------------------------------------------------------


<PAGE>

                                                                            Page
                                                                            ----
Part I - FINANCIAL INFORMATION

Item 1. Financial Statements
        Consolidated Balance Sheet as of June 28, 2003                       3
        Consolidated Statements of Income for the Three and Six Months
          Ended June 28, 2003 and June 29, 2002                              4
        Consolidated Statements of Cash Flows for the Six Months Ended
          June 28, 2003                                                      5
        Notes to Consolidated Statements                                     6

Item 2. Management's Discussion and Analysis of Financial Condition and
        Results of Operations                                                8

Item 3. Controls and Procedures                                             10


Part II - OTHER INFORMATION

Item 1. Legal Proceedings                                                   10
Item 2. Changes in Securities                                               10
Item 3. Defaults Upon Senior Securities                                     10
Item 4. Submission of Matters to a Vote of Security Holders                 10
Item 5. Other Information                                                   10
Item 6. Exhibits and Reports on Form 8-K                                    10
Signature                                                                   11
Certifications Certifications - Chief Financial Officer and
     Chief Executive Officer                                                12



                                       2
<PAGE>


Part I.  FINANCIAL INFORMATION

Item 1.  Financial Statements
<TABLE>

                             SPECTRUM LABORATORIES, INC.
                              Consolidated Balance Sheet
                                 AS OF JUNE 28, 2003
                       (DOLLARS IN THOUSANDS, EXCEPT PAR VALUE)
                                     (UNAUDITED)
<CAPTION>
<S>                                                                         <C>
ASSETS
CURRENT ASSETS:
    Cash and cash equivalents                                               $ 4,829
    Accounts receivable                                                       1,606
    Inventories                                                               2,107
    Prepaid expenses                                                            297
    Deferred taxes                                                              528
    Tax refund receivable                                                        62
                                                                            --------

        Total current assets                                                  9,429

EQUIPMENT AND LEASEHOLD IMPROVEMENTS                                          2,875
GOODWILL, not subject to amortization                                         1,122
DEFERRED TAXES                                                                1,424
PATENTS, subject to amortization, net of accumulated amortization of $151       599
OTHER ASSETS                                                                     33
                                                                            --------

        Total assets                                                        $15,482
                                                                            ========


LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
    Current maturities of long-term debt                                    $   960
    Accounts payable                                                            463
    Accrued expenses and other current liabilities                              684
                                                                            --------

        Total current liabilities                                             2,107

LONG-TERM DEBT, net of current maturities                                     2,265

MINORITY INTEREST                                                             1,755

STOCKHOLDERS' EQUITY:
    Common stock, $.01 par value, 25,000,000 shares authorized;
      5,312,468 shares issued and outstanding                                    53
    Preferred stock, par value $.01; 10,000,000 shares authorized;
      none issued and outstanding                                                --
    Additional paid-in capital                                                8,485
    Retained earnings                                                           817
                                                                            --------

        Total stockholders' equity                                            9,355
                                                                            --------

        Total liabilities and stockholders' equity                          $15,482
                                                                            ========

                   See Notes to Consolidated Financial Statements.

                                          3
</TABLE>
<PAGE>
<TABLE>

                                  SPECTRUM LABORATORIES, INC.
                               CONSOLIDATED STATEMENTS OF INCOME
                         (IN THOUSANDS, EXCEPT FOR PER SHARE AMOUNTS)
                                          (UNAUDITED)
<CAPTION>
                                              Three Months Ended         Six Months Ended
                                           ------------------------  ------------------------
                                             June 28,    June 29,     June 28,     June 29,
                                              2003         2002         2003         2002
                                           -----------  -----------  -----------  -----------
<S>                                        <C>          <C>          <C>          <C>
NET SALES                                  $    3,327   $    3,338   $    6,785   $    6,592

COSTS AND EXPENSES
    Cost of sales                               1,772        1,818        3,566        3,615
    Selling, general and administrative         1,083        1,065        2,138        2,027
    Research and development                      212          198          418          361
    Other expense, primarily interest              36            3           72           30
                                           -----------  -----------  -----------  -----------

        Total costs and expenses                3,103        3,084        6,194        6,033
                                           -----------  -----------  -----------  -----------

Income before provision for income taxes          224          254          591          559

Provision for income taxes                         62          102          172          223
                                           -----------  -----------  -----------  -----------

        Net income                         $      162   $      152   $      419   $      336
                                           ===========  ===========  ===========  ===========

Earnings per share:
    Basic                                  $     0.03   $     0.03   $     0.08   $     0.06
                                           ===========  ===========  ===========  ===========

    Diluted                                $     0.03   $     0.03   $     0.08   $     0.06
                                           ===========  ===========  ===========  ===========


Weighted average shares outstanding:
    Basic                                       5,312        5,312        5,312        5,312
                                           ===========  ===========  ===========  ===========

    Diluted                                     5,396        5,356        5,384        5,374
                                           ===========  ===========  ===========  ===========


                       See Notes to Consolidated Financial Statements.

                                              4
</TABLE>
<PAGE>

                           SPECTRUM LABORATORIES, INC.
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                SIX MONTHS ENDED JUNE 28, 2003 AND JUNE 29, 2002
                                 (IN THOUSANDS)
                                   (UNAUDITED)


                                                               2003       2002
                                                             --------   --------
CASH FLOWS FROM OPERATING ACTIVITIES:
    Net income                                               $   419    $   336
    Adjustments to reconcile net income to net cash
      provided by operating activities:
      Depreciation and amortization                              376        325
      Noncash compensation                                         6         14
      Change in working capital components:
        Decrease (Increase) in accounts receivable               200       (106)
        (Increase) Decrease in inventories                      (341)        68
        (Increase) in prepaid expenses                           (64)      (133)
        (Decrease) Increase in accounts payable                 (101)       201
        (Decrease) Increase in accrued expenses                  (12)        82
                                                             --------   --------

        NET CASH PROVIDED BY OPERATING ACTIVITIES                483        787
                                                             --------   --------

CASH FLOWS FROM INVESTING ACTIVITIES:
    Acquisition of equipment and leasehold improvements         (300)      (248)
    Acquisition of patents                                        --       (250)
                                                             --------   --------

        NET CASH (USED IN) INVESTING ACTIVITIES                 (300)      (498)
                                                             --------   --------

CASH FLOWS FROM FINANCING ACTIVITIES:
    Principal payments of long-term debt                        (463)      (395)
                                                             --------   --------

        NET DECREASE IN CASH AND CASH EQUIVALENTS               (280)      (106)


CASH AND CASH EQUIVALENTS, beginning of period                 5,109      3,027
                                                             --------   --------

CASH AND CASH EQUIVALENTS, end of period                     $ 4,829    $ 2,921
                                                             ========   ========

                See Notes to Consolidated Financial Statements.

                                       5



<PAGE>

NOTES TO CONSOLIDATED STATEMENTS

Note 1

Basis of Presentation - The accompanying unaudited financial statements
consolidate the accounts of Spectrum Laboratories, Inc. and its subsidiaries,
SLI Acquisition Corp., Spectrum Europe B.V. and Spectrum Chromatography
(collectively, the Company). All significant intercompany transactions have been
eliminated in consolidation. In the opinion of management, the accompanying
unaudited interim consolidated financial statements contain all adjustments
(consisting only of normal recurring adjustments) necessary to present fairly
the financial position of the Company as of June 28, 2003 and the results of its
operations and its cash flows for the six months ended June 28, 2003 and June
29, 2002. Certain information and footnote disclosures normally included in the
financial statements have been condensed or omitted pursuant to rules and
regulations of the Securities and Exchange Commission, although the Company
believes that the disclosures in the unaudited interim financial statements are
adequate to make the information presented not misleading.

ACCOUNTING FOR STOCK-BASED COMPENSATION - In December 2002, the FASB issued SFAS
No. 148, Accounting for Stock-Based Compensation - Transition and Disclosure.
This Statement amends SFAS No 123, Accounting for Stock-Based Compensation, to
provide alternative methods of transition for an entity that voluntarily changes
to the fair value-based method of accounting for stock-based employee
compensation. This Statement also amends the disclosure requirement of SFAS No.
123 to require prominent disclosure in both annual and interim financial
statements about the effect on reported net income (loss) of an entity's
accounting policy decisions with respect to stock-based employee compensation.
The Company adopted this Statement in fiscal year 2002.

The Company accounts for stock-based employee compensation under the
requirements of Accounting Principles Board (APB) Opinion No. 25, which does not
require compensation to be recorded if the consideration to be received is at
least equal to fair value at the measurement date. Nonemployee stock-based
transactions are accounted for under the requirements of the Financial
Accounting Standards Board's Statement of Financial Accounting Standards No.
123, ACCOUNTING FOR STOCK-BASED COMPENSATION, which requires compensation to be
recorded based on the fair value of the securities issued or the services
received, whichever is more reliably measurable.

SFAS No. 123 requires the disclosure of pro forma net income and earnings per
share had the Company adopted the fair value method. Under SFAS No. 123, the
fair value of stock-based awards to employees is calculated through the use of
option-pricing models, even though such models were developed to estimate the
fair value of freely tradable, fully transferable options with vesting
restrictions which significantly differ from the Company's stock option awards.
These models also require subjective assumptions, including future stock price
volatility and expected time to exercise, which greatly affect the calculated
value. The Company's calculations for the options granted were made using the
Black-Scholes option-pricing model.

The calculations are based on a single-option valuation approach and forfeitures
are recognized as they occur. The following table illustrates the effect on net
income and earnings per share had compensation cost for stock-based compensation
been determined based on the grant date fair values of awards for the three and
six months ended June 28, 2003 and June 29, 2002, respectively as detailed on
the following page:



                                       6
<PAGE>


Note 1 Accounting for Stock-based Compensation (Continued):
<TABLE>
<CAPTION>
                                                Three Months Ended             Six Months Ended
                                            ---------------------------   ---------------------------
                                            June 28, 2003 June 29, 2002   June 28, 2003 June 29, 2002
                                            ------------   ------------   ------------   ------------
<S>                                         <C>            <C>            <C>            <C>
Net income:
    As reportedd                            $   162,000    $   152,000    $   419,000    $   336,000
      Add total stock-based employee
      compensation expense determined
      under APB opinion 25,
      net of related tax effects                  3,000          7,000          6,000         14,000
      (Deduct) total stock-based employee
      compensation expense determined
      under fair value based for all
      awards, net of related tax benefits       (17,000)       (19,000)       (33,000)       (38,000)
                                            ------------   ------------   ------------   ------------

     Pro forma                              $   148,000    $   140,000    $   392,000    $   312,000
                                            ============   ============   ============   ============

Basic earnings per share:
    As reportedd                            $      0.03    $      0.03    $      0.08    $      0.06
    Pro forma                               $      0.03    $      0.03    $      0.07    $      0.06
Diluted earnings per share:
    As reportedd                            $      0.03    $      0.03    $      0.08    $      0.06
    Pro forma                               $      0.03    $      0.03    $      0.07    $      0.06

Weighted average shares outstanding:
    Basic                                     5,312,000      5,312,000      5,312,000      5,312,000
                                            ============   ============   ============   ============

    Diluted                                   5,396,000      5,356,000      5,384,000      5,374,000
                                            ============   ============   ============   ============
</TABLE>


Note 2 - Inventories

Inventories are stated at the lower of cost, determined using the first-in,
first-out method, or net realizable value and are composed of the following (in
thousands):

          Raw materials                                      $ 1,171
          Work in process                                        283
          Finished goods                                         653
                                                             --------

                                                             $ 2,107
                                                             ========

Note 3 - Earnings per Share

Basic earnings per share is computed by dividing the net income attributable to
the common stockholders by the weighted average number of common shares
outstanding during the period. There is no adjustment in the net income
attributable to common stockholders. Diluted earnings per share reflect the
potential dilution that could occur from common shares issuable through stock
options (83,122 and 71,872 shares in the fiscal year 2003 three and six month
periods respectively and 43,178 and 61,330 shares in the fiscal 2002 three and
six month periods, respectively).


                                       7
<PAGE>


Note 4 - Income Taxes

In assessing the realizability of deferred tax assets, management has estimated
that it is likely that approximately $1,500,000 will not be realized. This
valuation allowance represents a portion of net operating loss carryforwards
attained through a prior business acquisition. As further discussed below, tax
law limits the use of an acquired entity's net operating loss carryforwards to
subsequent taxable income of the consolidated entity. Management will continue
to evaluate the realizability of the deferred tax assets by assessing the need
for and amount of a valuation allowance.

At December 28, 2002, the Company had approximately $6.2 million in net
operating loss carryforwards for federal income tax purposes available to offset
future taxable income. Certain of these loss carryforwards are limited to
approximately $298,000 annually. Any unused net operating loss is carried
forward. As a result of the limitation discussed above, it is probable that
approximately $4.5 million of the Company's net operating loss will expire
without utilization. Loss carryforwards for tax purposes expire in amounts and
by fiscal year as follows: 2004 $1,046,000; 2005 $2,836,000; 2006 $1,820,000;
2007 $274,000; 2010 $40,000; 2012 $114,000 and 2018 $85,000.

Note 5 - Product Group Information

The Company's product groups are based on specific product characteristics and
are grouped into laboratory products and operating room disposable products.
Laboratory products consist primarily of: (1) membranes used to concentrate,
separate and purify dissolved or suspended molecules that are sold primarily to
laboratories and (2) hollow fiber membrane devices that allow components
retained by a membrane to be concentrated including filters utilized for micro
and ultrafiltration separations that are sold to biotech and pharmaceutical
companies. Operating room disposable products consist primarily of sterile
plastic surgical drapes and cloth bandages that are sold primarily to hospitals.

Revenue by product group is as follows (in thousands):

                                         Three Months Ended    Six Months Ended
                                          ------------------  ------------------
                                          June 28,  June 29,  June 28,  June 29,
                                            2003      2002      2003      2002
                                           ------    ------    ------    ------

Laboratory products                         2,904     2,823     5,942     5,737
Operating room disposable products            423       515       843       855
                                           ------    ------    ------    ------

                                           $3,327    $3,338    $6,785    $6,592
                                           ======    ======    ======    ======

Note 5 - Option Plan

The Company had two options plans referred to as the 1995 Option Plan and the
2000 Option Plan with 200,000 and 300,000 shares of common stock, respectively
reserved for option grants to key employees, directors and consultants. In July
2002, the shareholders' approved merging the 1995 Option Plan and the 2000
Option Plan into one plan to be referred to as the 2000 Option Plan (the "2000
Option Plan"). In addition, shareholders approved the number of shares available
to grant under the 2000 Option Plan by 100,000 to a total of 600,000. As of June
28, 2003, there were 436,300 options outstanding under the 2000 Option Plan.
There were no grants or cancellations of options during the six months ended
June 28, 2003.


                                       8
<PAGE>

Item 2. Management's Discussion and Analysis of Financial Condition and Results
        of Operations

The following discussion should be read in conjunction with the Consolidated
Financial Statements of Spectrum Laboratories, Inc. and Notes thereto contained
elsewhere within this Report on Form 10-QSB. Except for the historical
information contained herein, the following discussion may contain
forward-looking statements that involve risks and uncertainties. The actual
future results of the Company could differ materially from those discussed here.
Factors that could cause or contribute to such differences include, but are not
limited to, those discussed in this report and those factors discussed in the
Company's Form 10-KSB for the year ended December 28, 2002 as filed with the
Securities and Exchange Commission and, from time to time, in the Company's
other reports on file with the Commission.

Results of Operations

Sales

Sales for the second quarter ended June 28, 2003 (2nd quarter) were marginally
lower by $11,000 (0.3%) when compared to the second quarter of 2002. The
marginally lower sales was principally due to timing in the Operating Room
Disposable segment as reported 2003 2nd quarter sales for this segment decreased
$92,000 (18%) from 2nd quarter 2002 although on a year to date basis sales for
this segment are only down marginally by $12,000 (1.4%). Consolidated sales for
the 6 month period ended June 28, 2003 totaled $6,785,000, an increase of
$193,000 (2.9%) when compared to year to date 2002.

Gross Margin

Gross Margin for the 6 month period ended June 28, 2003 was $3,219,000 (47.4%)
versus the similar period in 2002 of $2,977,000 (45.2%). The increase in gross
margin percentage was due to both product and customer mix. Gross margin also
benefited from the positive impact of the increase of the Euro exchange rate
considering Spectrum BV inventory purchases are denominated in U.S. dollars.

Selling, General & Administrative and Research & Developmental Expenses
("Expenses")

Expenses for the 2nd quarter of 2003 were $1,295,000, a marginal increase of
$32,000 (2.5%) from the 2nd quarter of 2002. Expenses for the 6 month period
ended June 28, 2003 were $2,556,000, an increase of $168,000 (7.0%) over the
same period in 2002. The increase in expenditures was principally attributable
to an $80,000 charitable contribution the Company made in the first quarter as
well as a $51,000 increase in depreciation expense reflecting of the additional
equipment the Company has acquired. In addition, the Company continues to issue
its BioProcessor newsletter to its customers. The Company has issued two
BioProcessor newsletters in the first six months of 2003, the related
expenditures plus the cost of sales of catalogs and The ABCs of Filtration book
distributed during the six month period resulted in advertising expenses
increasing by $38,000 (20%) versus 2002.

Income before Taxes

The net of the above resulted in income before taxes in the 2nd quarter of 2003
of $224,000, a decrease of $30,000 (11.8%) over the 2nd quarter of 2002. Income
before taxes for the 6 month period ended June 28, 2003 was $591,000 and
increase of $32,000 (5.7%) over the same period in 2002. Considering the
historical utilization and availability of tax credits which are anticipated for
the current fiscal year, management believes an effective tax rate of 30% to be
appropriate.

Liquidity and Capital Resources

During the first six months of 2003, the Company generated approximately
$483,000 of cash from operating activities. Cash utilized for working capital
requirements totaled $318,000 principally related to the increase in inventory
of $341,000. The decrease in Accounts Receivable of $200,000 was primarily
offset by an increase in Prepaid Expenses and a decrease in Accounts
Payable/Accrued Expenses. The increase in inventory principally relates to the
Company's efforts to maintain a broader breath of product on hand to respond to
customer requests.

The above discussed cash from operating activities was then offset by $463,000
in bank loan payments and $300,000 for the acquisition of equipment. This
resulted in a net decrease in cash for the period of approximately $280,000 to a
cash balance at June 28, 2003 of $4,829,000.

                                       9
<PAGE>

As noted in prior reports, the Company had committed $105,000 in the fourth
quarter of 2002 for a license relating to new software in order to operate its
business more efficiently. This amount has now been expended as of June 28,
2003. The Company implemented its new business software immediately after its
June 28, 2003 quarter end and thus is now subsequently operating under its new
business software. The total cost of the software implementation was estimated
at $350,000. Although not all costs have been incurred, preliminary, it appears
the implementation costs will approximate budget.

The Company is obligated under the terms of various operating lease agreements
for manufacturing, warehouse and office facilities. Certain of these leases
provide for rent escalation adjustments. Minimum future rental payments under
these operating lease agreements for the third and fourth quarters ending
December 28, 2003 and the subsequent years ending December 31 are as follows:
third and fourth quarters 2003 $232,000; years ending 2004 $341,000; and 2005
$184,000 (total $757,000).

The Company's management believes that cash on hand and cash expected to be
generated from operations will be sufficient to meet cash requirements for the
next twelve months.

Item 3.  Controls and Procedures

As of the end of the period covered by this report, the Company conducted an
evaluation, under the supervision and with the participation of the principal
executive officer and principal financial officer, of the Company's disclosure
controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the
Securities Exchange Act of 1934 (the "Exchange Act")). Based on this evaluation,
the principal executive officer and principal financial officer concluded that
the Company's disclosure controls and procedures are effective to ensure that
information required to be disclosed by the Company in reports that it files or
submits under the Exchange Act is recorded, processed, summarized and reported
within the time periods specified in Securities and Exchange Commission rules
and forms. There was no change in the Company's internal control over financial
reporting during the Company's most recently completed fiscal quarter that has
materially affected, or is reasonably likely to materially affect, the Company's
internal control over financial reporting.



Part II.  OTHER INFORMATION

Item 1.  Legal Proceedings
          None

Item 2.  Change in Securities and Use of Proceeds
          None

Item 3.  Defaults Upon Senior Securities
          None

Item 4.  Submission of Matters to a Vote of Security Holders
          None

Item 5.  Other Information
          None

Item 6.  Exhibits and Reports on Form 8-K

         (a) Exhibits

31.1     Certification of Chief Financial Officer of Spectrum Laboratories, Inc.

31.2     Certification of Chief Executive Officer of Spectrum Laboratories, Inc.

32       Certification of Chief Executive Officer and Chief Financial Officer of
         Spectrum Laboratories, Inc.


         (b) The Company filed no reports on Form 8-K during the quarter ended
June 28, 2003.




                                       10
<PAGE>


SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized, on August 11, 2003.

SPECTRUM LABORATORIES, INC.
(Registrant)





/s/  F. Jesus Martinez
-----------------------------
Signature

F. Jesus Martinez
President






/s/  Brian A. Watts
-----------------------------
Signature

Brian A. Watts
Chief Financial Officer/Vice President of Finance











                                       11
<PAGE>


Certifications

Chief Financial Officer

I, Brian A. Watts Chief Financial Officer, certify that:

1.       I have reviewed this quarterly report on Form 10-QSB of Spectrum
         Laboratories, Inc.;

2.       Based on my knowledge, this report does not contain any untrue
         statement of a material fact or omit to state a material fact necessary
         to make the statements made, in light of the circumstances under which
         such statements were made, not misleading with respect the period
         covered by this report;

3.       Based on my knowledge, the financial statements, and other financial
         information included in this report, fairly present in all material
         respects the financial condition, results of operations and cash flows
         of the small business issuer as of, and for, the periods presented in
         this report;

4.       The small business issuer's other certifying officer and I are
         responsible for establishing and maintaining disclosure controls and
         procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
         and internal control over financial reporting (as defined in Exchange
         Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and
         have:

         a)       Designed such disclosure controls and procedures, or caused
                  such disclosure controls and procedures to be designed under
                  our supervision, to ensure that material information relating
                  to the small business issuer, including its consolidated
                  subsidiaries, is made known to us by others within those
                  entities, particularly during the period in which this report
                  is being prepared;

         b)       Designed such internal control over financial reporting, or
                  caused such internal control over financial reporting to be
                  designed under our supervision, to provide reasonable
                  assurance regarding the reliability of financial reporting and
                  the preparation of financial statements for external purposes
                  in accordance with generally accepted accounting principles;

         c)       Evaluated the effectiveness of the small business issuer's
                  disclosure controls and procedures and presented in this
                  report our conclusions about the effectiveness of the
                  disclosure controls and procedures, as of the end of the
                  period covered by this report based on such evaluation; and

         d)       Disclosed in this report any change in the small business
                  issuer's internal control over financial reporting that
                  occurred during the small business issuer's most recent fiscal
                  quarter that has materially affected, or is reasonably likely
                  to materially affect, the small business issuer's internal
                  control over financial reporting; and

5.       The small business issuer's other certifying officer and I have
         disclosed, based on our most recent evaluation of internal control over
         financial reporting, to the small business issuer's auditors and the
         audit committee of the small business issuer's board of directors:

         a)       All significant deficiencies and material weakness in the
                  design or operation of internal control over financial
                  reporting which are reasonably likely to adversely affect the
                  small business issuer's ability to record, process, summarize
                  and report financial information; and

         b)       Any fraud, whether or not material, that involves management
                  or other employees who have a significant role in the small
                  business issuer's internal control over financial reporting.

Dated: August 11, 2003



/s/  Brian A. Watts
-----------------------------
Signature

Brian A. Watts
Chief Financial Officer/Vice President of Finance


                                       12
<PAGE>

Chief Executive Officer

I, Roy T. Eddleman Chief Executive Officer, certify that:

1.       I have reviewed this quarterly report on Form 10-QSB of Spectrum
         Laboratories, Inc.;

2.       Based on my knowledge, this report does not contain any untrue
         statement of a material fact or omit to state a material fact necessary
         to make the statements made, in light of the circumstances under which
         such statements were made, not misleading with respect the period
         covered by this report;

3.       Based on my knowledge, the financial statements, and other financial
         information included in this report, fairly present in all material
         respects the financial condition, results of operations and cash flows
         of the small business issuer as of, and for, the periods presented in
         this report;

4.       The small business issuer's other certifying officer and I are
         responsible for establishing and maintaining disclosure controls and
         procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
         and internal control over financial reporting (as defined in Exchange
         Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and
         have:

         a)       Designed such disclosure controls and procedures, or caused
                  such disclosure controls and procedures to be designed under
                  our supervision, to ensure that material information relating
                  to the small business issuer, including its consolidated
                  subsidiaries, is made known to us by others within those
                  entities, particularly during the period in which this report
                  is being prepared;

         b)       Designed such internal control over financial reporting, or
                  caused such internal control over financial reporting to be
                  designed under our supervision, to provide reasonable
                  assurance regarding the reliability of financial reporting and
                  the preparation of financial statements for external purposes
                  in accordance with generally accepted accounting principles;

         c)       Evaluated the effectiveness of the small business issuer's
                  disclosure controls and procedures and presented in this
                  report our conclusions about the effectiveness of the
                  disclosure controls and procedures, as of the end of the
                  period covered by this report based on such evaluation; and

         d)       Disclosed in this report any change in the small business
                  issuer's internal control over financial reporting that
                  occurred during the small business issuer's most recent fiscal
                  quarter that has materially affected, or is reasonably likely
                  to materially affect, the small business issuer's internal
                  control over financial reporting; and

5.       The small business issuer's other certifying officer and I have
         disclosed, based on our most recent evaluation of internal control over
         financial reporting, to the small business issuer's auditors and the
         audit committee of the small business issuer's board of directors:

         a)       All significant deficiencies and material weakness in the
                  design or operation of internal control over financial
                  reporting which are reasonably likely to adversely affect the
                  small business issuer's ability to record, process, summarize
                  and report financial information; and

         b)       Any fraud, whether or not material, that involves management
                  or other employees who have a significant role in the small
                  business issuer's internal control over financial reporting.

Dated: August 11, 2003



/s/  Roy T. Eddleman
-----------------------------
Signature

Roy T. Eddleman
Chief Executive Officer & Chairman

                                       13